The significance of genetic polymorphisms in modulating the response to lipid-lowering drugs

Pharmacogenomics

Volumn 2, Issue 2, 2001, Pages 107-121

  Hoffmann, M M ^a   Winkelmann, B R ^a   Wieland, H ^a   Marz W ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Apolipoprotein; Cholesterol ester transfer protein (CETP); Dyslipidaemia; Fibrates; HMG CoA reductase inhibitors; LDL receptor; Pharmacogenetics; Polymorphisms; Single nucleotide polymorphisms (SNPs); Sterol regulatory element binding protein (SREBP)

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; COLESTIPOL; COLESTYRAMINE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; PROBUCOL; SIMVASTATIN; STROMELYSIN;

AGE; CARDIOVASCULAR RISK; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; FAMILIAL HYPERCHOLESTEROLEMIA; GENDER; GENETIC DISORDER; GENETIC POLYMORPHISM; GENOME; HUMAN; HYPERLIPOPROTEINEMIA; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; METABOLIC DISORDER; MODULATION; MYOSITIS; PHENOTYPE; POPULATION; REVIEW; RHABDOMYOLYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; ANTILIPEMIC AGENTS; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS; POLYMORPHISM, GENETIC;

EID: 0035020373     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.2.2.107     Document Type: Review

References (101)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4s)
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
3. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
4. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
6. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor
7. Sterol regulatory element binding protein (SREBPs): Key regulators of nutritional homeostasis and insulin action
8. Sterol regulation of acetyl coenzyme A carboxylase: A mechanism for coordinate control of cellular lipid
9. Sterol regulation of fatty acid synthase promoter. Coordinate feedback regulation of two major lipid pathways
10. Regulation of the mevalonate pathway
11. New insights into the pharmacodynamic and pharmacokinetic properties of statins
12. Pleiotropic effects of statins in atherosclerosis and diabetes
13. Drug interactions and the statins
14. CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A*1B5′- promoter region polymorphism
15. Update: Genetic polymorphism of drug metabolizing enzymes in humans
16. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment
17. Pharmacogenetics in the practice of laboratory medicine
18. Isolation and radiation hybrid mapping of a highly polymorphic CA repeat sequence at the SREBP cleavage-activating protein (SCAP) locus
19. A common Ile796Val polymorphism of the human SREBP cleavage-activating protein (SCAP) gene
20. Mutations in the apolipoprotein (apo) B-100 receptor-binding region: Detection of apoB-100 (Arg3500-Trp) associated with two new haplotypes and evidence that apoB-100 (Glu3405-Gln) diminishes receptor-mediated uptake of LDL
21. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100
22. Accumulation of 'small dense' low density lipoproteins in a homozygous patient with familial defective apolipoprotein B-100 results from heterogenous interaction of LDL subfractions with the LDL receptor
23. Familial defective apolipoprotein B-100: A review, including some comparisons with familial hypercholesterolaemia
24. Homozygous familial defective apolipoprotein B-100. Enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs
25. Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects
26. Familial defective apolipoprotein B-100
27. [Detection of the Arg 3500-Gln mutation of B apolipoprotein. Value in clinical practice]
28. DNA polymorphism studies. Approaches to elucidating multifactorial ischaemic heart disease: The apoB gene as an example
29. Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia
30. Familial Hypercholesterolemia
31. Low-density lipoprotein receptor gene (LDLR) worldwide website in familial hypercholesterolaemia: Update, new features and mutation analysis
32. Heterozygous familial hypercholesterolaemia: The influence of the mutation type of the low-density-lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment
33. Response to HMG CoA reductase inhibitors in heterozygous familial hypercholesterolemia due to the 10-kb deletion ('French Canadian mutation') of the LDL receptor gene
34. Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia
35. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia
36. Association of the A-204C polymorphism in the cholesterol7alpha-hydroxylase gene with variations in plasma low density lipoprotein cholesterol levels in the Framingham Offspring Study
37. Apolipoprotein E: From atherosclerosis to Alzheimer's disease and beyond
38. The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia
39. Influence of apoE polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia
40. Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia
41. The effect of the apolipoprotein E phenotype on cholesteryl ester transfer protein activity, plasma lipids and apolipoprotein A I levels in hypercholesterolaemic patients on colestipol and lovastatin treatment
42. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism
43. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy
44. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy
45. The apolipoprotein ε4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: A substudy of the Scandinavian simvastatin survival study
46. The role of hepatic lipase in lipoprotein metabolism and atherosclerosis
47. Evidence for a new pathophysiological mechanism for coronary artery disease regression: Hepatic lipase-mediated changes in LDL density
48. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid lowering treatment
49. Three polymorphisms associated with low hepatic lipase activity are common in African Americans
50. Apolipoprotein A-I: Structure-function relationships
51. Mild association between the A/G polymorphism in the promoter of the apolipoprotein A-I gene and apolipoprotein A-I levels: A meta-analysis
52. The G/A promoter polymorphism at the apoAI gene locus predicts individual variability in fasting and postprandial responses to the HMG CoA reductase inhibitor atorvastatin
53. The role of apolipoprotein A-IV in food intake regulation
54. Lipoprotein(a) as a risk factor for coronary artery disease
55. Genetic architecture and evolution of the lipoprotein(a) trait
56. Effects of lovastatin (20-80 mg daily) on lipoprotein fractions in patients with severe primary hypercholesterolemia
57. Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration
58. Preliminary report: Genetic variation in the human stromelysin promotor is associated with progression of coronary atherosclerosis
59. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis
60. The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study
61. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis
62. In search of perverse polymorphisms
63. Polymorphism of the cholesteryl ester transfer protein gene
64. Polymorphism of the cholesteryl ester transfer protein gene
65. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: The Framingham study
66. A polymorphism of the Cholesteryl Ester Transfer Protein (CETP) gene predicts cardiovascular events in the West of Scotland Coronary Prevention Study (WOSCOPS)
67. Mechanism of action of fibrates on lipid and lipoprotein metabolism
68. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis
69. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: No alteration in adipose tissue of obese and NIDDM patients
70. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene
71. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase
72. An enzymatic explanation of the differential effects of oleate and gemfibrozil on cultured hepatocyte triacylglycerol and phosphatidylcholine biosynthesis and secretion
73. PPARα and PPARγ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
74. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia
75. Molecular scanning of the human PPARα gene. Association of the l162v mutation with hyperapobetalipoproteinemia
76. Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects
77. The human peroxisome proliferator-activated receptor α gene: Identification and functional characterization of two natural allelic variants
78. Comparison of the effect of bezafibrate on improvement of atherogenic lipoproteins in Japanese familial combined hyperlipidemic patients with or without impaired glucose tolerance
79. DNA polymorphisms of apolipoprotein B and AI/CIII genes and response to gemfibrozil treatment
80. Apolipoprotein E polymorphism influences the serum cholesterol response to dietary intervention
81. Influence of apolipoprotein E polymorphism on bezafibrate treatment response in dyslipidemic patients
82. Effect of Gevilon therapy and its relation to E polymorphism
83. Apolipoprotein E and complement C3 polymorphism and their role in the response to gemfibrozil and low fat low cholesterol therapy
84. Interruption of the enterohepatic circulation of bile acids in man: Comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism
85. Bile acid synthesis in humans: Regulation of hepatic microsomal cholesterol 7 alpha-hydroxylase activity
86. Contribution of cholesterol7α-hydroxylase to the regulation of lipoprotein metabolism
87. Linkage between cholesterol 7α-hydroxylase and high plasma low-density lipoprotein cholesterol concentrations
88. Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism
89. Sterol regulatory element-binding proteins: Activators of cholesterol and fatty acid biosynthesis
90. Nicotinic acid and its derivatives
91. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia
92. Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly
93. The assembly and secretion of apolipoprotein B-containing lipoproteins
94. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits
95. A common functional polymorphism in the promoter region of the microsomal triglyceride transfer protein gene influences plasma LDL levels
96. Identification of two polymorphisms in the promoter of the microsomal triglyceride transfer protein (MTP) gene. Lack of association with lipoprotein profiles
97. Absence of association between genetic variation in the promoter of the microsomal triglyceride transfer protein gene and plasma lipoproteins in the Framingham Offspring Study
98. Mechanisms of high-density lipoprotein reduction after probucol treatment: Changes in plasma cholesterol esterification/transfer and lipase activities
99. Effects of probucol on homozygous cases of familial hypercholesterolemia
100. Apolipoprotein E polymorphism and plasma cholesterol response to probucol
101. Effects of probucol on plasma lipids and lipoproteins in familial hypercholesterolemic patients with and without apolipoprotein E4